FDA approves ibrutinib for chronic lymphocytic leukaemia

The US Food and Drug Administration (FDA) has expanded the approved use of ibrutinib (Imbruvica) for chronic lymphocytic leukaemia (CLL) patients who have received at least one previous therapy. Ibrutinib is an oral Bruton’s tyrosine kinase inhibitor. Read more here.